XBiotech has received City of Austin approval to begin excavation for site preparation and groundwork is expected to begin during the first quarter of 2024.
The new four-storey building, to be located close to the existing 46,000 sqft manufacturing and R&D facility, will provide key infrastructure to support commercialisation plans for the company’s Natrunix rheumatology programme.
The new facility will house clinical and medical operations, commercialisation teams, and even incorporate wet laboratories to enable ongoing infectious disease programmes.
In keeping with XBiotech’s desire to preserve the woodlands nature on the 48 acre campus, a subterranean parking garage is being constructed to minimize footprint and ecological impact of the new structure.
John Simard, President and CEO of XBiotech, commented: “We are excited to begin construction of what will be a unique and remarkable R&D facility. It will add significant operational capability to our existing manufacturing and R&D operations on the campus, and will create among the most capable biotechnology operations in Texas.”